TerrAscend Corp.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 14, 2022 and accepted by EDGAR at Nov 14, 2022, 16:05 ET.
Management's discussion and analysis
As filed, 49,749 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the Company's unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial information and the notes thereto included in the 2021 Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC, on March 17, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to the Company's plans and strategy for its business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth under "Risk Factors" in the 2021 Form 10-K, its actual results could differ materially from the results described in or implied by the "Cautionary Note Regarding Forward-Looking Statements" contained in this Quarterly Report on Form 10-Q and in the following discussion and analysis.
Unless otherwise noted, dollar amounts in this Item 2 are in thousands of U.S. dollars.
Overview
TerrAscend is a leading North American cannabis operator with vertically integrated operations in Pennsylvania, New Jersey, and California, licensed cultivation and processing operations in Michigan and Maryland, and licensed processing operations in Canada. TerrAscend operates a chain of Apothecarium dispensary retail locations, as well as scaled cultivation, processing, and manufacturing facilities on both the east and west coasts of the United States. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use market. Notwithstanding various states in the U.S. which have implemented medical marijuana laws, or which have otherwise legalized the use of cannabis, the use of cannabis remains illegal under U.S. federal law for any purpose, by way of the Controlled Substances Act of 1970.
TerrAscend operates under one operating segment which is the cultivation, production and sale of cannabis products.
TerrAscend’s portfolio of operating businesses and brands include:
- Gage Growth Corp. ("Gage"), a cultivator and processor in Michigan;
- Ilera Healthcare, a vertically integrated cannabis cultivator, processor and dispensary operator in Pennsylvania;
- TerrAscend NJ LLC, a majority owned subsidiary that holds a permit to operate up to three medical and/or recreational dispensaries in New Jersey with the ability to cultivate and process;
- The Apothecarium, consisting of retail dispensaries in California, Pennsylvania and New Jersey;
- Valhalla Confections, a provider of premium edible products;
- State Flower, a California-based cannabis producer operating a licensed cultivation facility in San Francisco, California;
- HMS Health, LLC and HMS Processing, LLC, a producer and seller of dried flower and oil products for the wholesale medical cannabis market in Maryland;
- TerrAscend Canada Inc., a Licensed Producer (as such term is defined in the Cannabis Act) of cannabis, with its current principal business activities including processing and sale of cannabis flower and oil products in Canada;
- Cookies Canada, the operator of a minority owned retail cannabis dispensary in Toronto, Canada; and
- Arise Bioscience, a manufacturer and distributor of hemp-derived products, located in Boca Raton, Florida.
Recent Developments
(i) On August 23, 2022, in order to expand its retail footprint in Michigan, the Company acquired KISA Enterprises MI, LLC and KISA Holdings, LLC (collectively, "Pinnacle"), a dispensary operator in Michigan, and related real estate for total consideration of $28,500. The transaction includes six retail dispensary licenses, five of which are currently operational and located in the cities of Addison, Buchanan, Camden, Edmore, and Morenci, Michigan. The Company intends to rebrand each of the dispensaries under either the Gage or Cookies retail brand.
(ii) During the nine months ended September 30, 2022, the Company commenced adult-use sales in New Jersey.
Pending and Subsequent Transactions
(i) On October 11, 2022, the subsidiaries of the Company, among others, entered into a loan agreement with Pelorus Fund REIT, LLC ("Pelorus") for a single-draw senior secured term loan ("Pelorus Term Loan") in an aggregate principal amount of $45,478. The Pelorus Term Loan bears interest of 12.77% per annum, which is based on a variable rate tied to the one month secured overnight financing rate (SOFR), subject to a 2.5% floor plus 9.5%, with interest-only payments for the first 36 months. The obligations of the borrowers under the Pelorus Term Loan are guaranteed by the Company, TerrAscend USA Inc. and certain other subsidiaries of the Company and secured by substantially all of the assets of the Company’s Maryland and New Jersey businesses, including certain real estate in Maryland and New Jersey. The Pelorus Term Loan matures on October 11, 2027.
(ii) On April 8, 2022, the Company entered into a definitive agreement to acquire Allegany Medical Marijuana Dispensary ("AMMD"), a medical dispensary in Maryland from Moose Curve Holdings, LLC. Under the terms of the agreement, the Company will acquire 100% equity interest in AMMD for total consideration of $10,000 in cash, in addition to acquiring the real estate for $1,700. The transaction is subject to customary closing conditions and regulatory approvals. The Company intends to rebrand the 8,000 square foot dispensary as The Apothecarium.
Results from Operations- Three months ended September 30, 2022 and September 30, 2021
The following tables represent the Company’s results from operations for the three months ended September 30, 2022 and 2021.
Revenue, net
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Revenue | $67,726 | $50,537 |
| Excise and cultivation taxes | (701) | (1,398) |
| Revenue, net | $67,025 | $49,139 |
| $ change | $17,886 | |
| % change | 36% |
The increase in net revenue at September 30, 2022 as compared to September 30, 2021 was due to an increase in retail revenue of $28,528 from $24,918 for the three months ended September 30, 2021 to $53,446 for the three months ended September 30, 2022. The increase in revenue was mainly due to adult use sales in New Jersey which commenced during the current year, as well as the acquisition of Gage (the "Gage Acquisition") in Michigan in March 2022. Retail dispensaries increased from 13 at September 30, 2021 to 30 at September 30, 2022.
The increase was partially offset by the decrease of $10,642 in wholesale revenue from $24,221 for the three months ended September 30, 2021 to $13,579 for the three months ended September 30, 2022, which was mainly related to challenging market dynamics in Pennsylvania.
Cost of Sales
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Cost of sales | $36,284 | $27,494 |
| Impairment and write downs of inventory | 6,378 | 148 |
| Total cost of sales | $42,662 | $27,642 |
| $ change | $15,020 | |
| % change | 54% | |
| Cost of sales as a % of revenue | 64% | 56% |
The increase in cost of sales for the three months ended September 30, 2022 as compared to the three months ended September 30, 2021 was driven mainly by the Gage Acquisition, as well as an increase in New Jersey due to the increase in adult use sales which commenced during the current year. The increase in cost of sales as a percentage of revenue was due to lower volumes in Pennsylvania leading to under-absorption, primarily related to lower wholesale flower sales, as well as operational challenges at the Company's cultivation facility in Frederick, Maryland as the Company transitioned to its Hagerstown location.
In addition, management wrote down its inventory by $6,378 and $148 for the three months ended September 30, 2022 and 2021, respectively. The inventory write-downs in the current year period were mainly due to inventory deemed unsaleable in its business in Canada. The inventory write-downs in the prior year period were related to inventory that the Company deemed unsaleable in its business in Canada.
General and Administrative Expense (G&A)
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| General and administrative expense | $29,385 | $21,320 |
| $ change | $8,065 | |
| % change | 38% | |
| G&A excluding share-based compensation | $26,680 | $16,142 |
| G&A excluding share-based compensation as a % of revenue | 40% | 33% |
The increase in G&A expenses was primarily a result of increased office and general expenses of $7,030 and increased salaries and wages of $3,268, which are primarily a result of the Gage Acquisition in March 2022.
Amortization and Depreciation Expense
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Amortization and depreciation | $3,032 | $1,947 |
| $ change | $1,085 | |
| % change | 56% |
The increase in amortization and depreciation expense for the three months ended September 30, 2022 as compared to the three months ended September 30, 2021 was primarily due to the Gage Acquisition during March 2022. The Company acquired retail licenses, which are amortized over a 15 year period. The fair value of the retail licenses at acquisition were $56,665.
Impairment of intangible assets
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Impairment of intangible assets | $152,928 | $- |
| $ change | $152,928 | |
| % change | 100% |
During the three months ended September 30, 2022, the Company performed impairment analyses over its indefinite lived and definite lived intangible assets acquired through the Gage Acquisition as the changes in the market expectations of cash flows in Michigan, as well as increased competition and supply in the state, were determined to be indicators of impairment. The Company determined that it was more likely than not that the carrying value of its definite lived retail and cultivation and processing licenses was greater than its fair value, and therefore recorded impairment of $78,998 and $54,730 for the retail and cultivation and processing licenses, respectively, reducing both the carrying values to $nil at September 30, 2022. Additionally, the Company recorded impairment of its indefinite lived brand intangible assets acquired through the Gage Acquisition of $19,200, reducing the carrying value of the brand intangibles to $57,985 at September 30, 2022.
Impairment of goodwill
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Impairment of goodwill | $178,314 | $- |
| $ change | $178,314 | |
| % change | 100% |
During the three months ended September 30, 2022, as it was determined that it was more likely than not that the Michigan reporting unit's fair value was less than its carrying value, a one-step goodwill quantitative impairment test was performed. As a result of the quantitative impairment test, the Company recorded impairment of goodwill of $178,314 at its Michigan reporting unit, reducing the carrying value of the goodwill acquired through the Gage Acquisition and Pinnacle Acquisition to $nil.
The impairment of goodwill for the three months ended September 30, 2021 was related to the Company's Florida reporting unit as the Company determined that the estimated cash flows of its Arise business did not support the carrying value of the intangible assets and goodwill. As a result, the Company recorded impairment to reduce the balance of goodwill at its Florida reporting unit to $nil.
Gain on fair value of warrants and purchase option derivative asset
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Gain on fair value of warrants and purchase option derivative asset | $(5,497) | $(69,016) |
| $ change | $63,519 | |
| % change | -92% |
The warrant liability was remeasured to fair value at September 30, 2022 using the Black Scholes Option Pricing Model ("Black Scholes model"). The Company recognized a gain on fair value of warrants of $5,497 during the three months ended September 30, 2022 as a result of the reduction of the Company's share price from June 30, 2022, as compared to September 30, 2022.
During the three months ended September 30, 2021, the Company recognized a gain on fair value of warrants of $69,016 as a result of the decrease in the Company's share price from June 30, 2021 to September 30, 2021 as well as warrants exercised during the three months ended September 30, 2021.
Finance and other expenses
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Finance and other expenses | $9,469 | $6,972 |
| $ change | $2,497 | |
| % change | 36% |
The increase in finance and other expenses for the three months ended September 30, 2022 as compared to the three months ended September 30, 2021 was primarily due to interest expense recognized on the loans acquired as part of the Gage Acquisition.
Transaction and restructuring costs
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Transaction and restructuring costs | $1,359 | $1,034 |
| $ change | $325 | |
| % change | 31% |
The transaction and restructuring costs for the three months ended September 30, 2022 were primarily due to personnel related reorganization and severance costs in Canada. The transaction and restructuring costs for the three months ended September 30, 2021 included legal costs related to the acquisitions of KCR, HMS, and Gage.
Unrealized and realized foreign exchange loss (gain)
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Unrealized and realized foreign exchange loss (gain) | $586 | $(1,256) |
| $ change | $1,842 | |
| % change | -147% |
The Company recognized an unrealized foreign exchange loss for the three months ended September 30, 2022 as compared to a gain for the three months ended September 30, 2021, which was a result of the remeasurement related to USD denominated liabilities recorded in C$ functional currency at the Company’s Canadian operations.
Unrealized and realized gain on investments
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Unrealized and realized gain on investments | $(231) | $- |
| $ change | $(231) | |
| % change | 100% |
The gain on investment during the three months ended September 30, 2022 was related to the revaluation of the investments acquired through the Gage Acquisition.
Provision for income taxes
| For the Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Provision for income taxes | $(34,033) | $4,999 |
| $ change | $(39,032) | |
| % change | -781% |
The decrease in provision for income taxes for the three months ended September 30, 2022 as compared to the three months ended September 30, 2021 was primarily driven by the decrease in pre-tax book income as a result of the impairment of intangible assets and goodwill recorded by the Company during the quarter.
Results from Operations- Nine months ended September 30, 2022 and September 30, 2021
The following tables represent the Company’s results from operations for the nine months ended September 30, 2022 and 2021.
Revenue, net
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Revenue | $183,538 | $169,010 |
| Excise and cultivation taxes | (2,050) | (7,794) |
| Revenue, net | $181,488 | $161,216 |
| $ change | $20,272 | |
| % change | 13% |
The increase in net revenue at September 30, 2022 as compared to September 30, 2021 was due to an increase of $64,862 in retail sales from $62,281 for the nine months ended September 30, 2021 to $127,143 for the nine months ended September 30, 2022. The increase in revenue was mainly due to adult use sales in New Jersey, which commenced during the current year, as well as the Gage Acquisition in March. Retail dispensaries increased from thirteen at September 30, 2021 to thirty at September 30, 2022.
The increase was partially offset by the decrease of $44,590 in wholesale revenue from $98,935 for the nine months ended September 30, 2021 to $54,345 for the nine months ended September 30, 2022, which was mainly related to challenging market dynamics in Pennsylvania.
Cost of Sales
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Cost of sales | $104,119 | $69,679 |
| Impairment and write downs of inventory | 14,873 | 263 |
| Total cost of sales | $118,992 | $69,942 |
| $ change | $49,050 | |
| % change | 70% | |
| Cost of sales as a % of revenue | 66% | 43% |
The increase in cost of sales for the nine months ended September 30, 2022 as compared to nine months ended September 30, 2021 was driven mainly by the Gage Acquisition, as well as an increase in New Jersey due to the increase in adult use sales which commenced during the current year. The increase in cost of sales as a percentage of revenue was due to lower volumes in Pennsylvania leading to under-absorption, primarily related to lower wholesale flower sales, as well as operational challenges at the Company's cultivation facility in Frederick, Maryland as the Company transitions to its Hagerstown location.
In addition, management wrote down its inventory by $14,873 and $263 for the nine months ended September 30, 2022 and 2021, respectively. The inventory write-downs in the current year period were mainly due to the write down of inventory to lower of cost or market which was related to the Company's operational reconfiguration of its cultivation facility in Pennsylvania, write downs of inventory related to the vape recall in Pennsylvania, as well as inventory deemed unsaleable in its business in Canada. The impairment recorded in the prior year period was due to obsolete or slow-moving inventory at the Company's Arise business and other inventory that the Company deemed unsaleable in its business in Canada.
General and Administrative Expense (G&A)
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| General and administrative expense | $85,918 | $62,462 |
| $ change | $23,456 | |
| % change | 38% | |
| G&A excluding share-based compensation | $75,394 | $49,069 |
| G&A excluding share-based compensation as a % of revenue | 42% | 30% |
The increase in G&A expenses was primarily a result of increased salaries and wages of $11,083, office and general expenses of $9,415, and sales and marketing of $4,672, which is primarily a result of the Gage Acquisition.
Amortization and Depreciation Expense
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Amortization and depreciation | $8,666 | $5,664 |
| $ change | $3,002 | |
| % change | 53% |
The increase in amortization and depreciation expense for the nine months ended September 30, 2021 as compared to September 30, 2020 was primarily due to the Gage Acquisition during March 2022. The company acquired retail licenses which are amortized over a 15 year period. The fair value of the retail licenses at acquisition was $53,321.
Impairment of intangible assets
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Impairment of intangible assets | $152,928 | $3,633 |
| $ change | $149,295 | |
| % change | 4109% |
During the nine months ended September 30, 2022, the Company performed impairment analyses over its indefinite lived and definite lived intangible assets acquired through the Gage Acquisition as the changes in the market expectations of cash flows in Michigan, as well as increased competition and supply in the state, were determined to be indicators of impairment. The Company determined that it was more likely than not that the carrying value of its definite lived retail and cultivation and processing licenses was greater than its fair value, and therefore recorded impairment of $78,998 and $54,730 for the retail and cultivation and processing licenses, respectively, reducing both the carrying values to $nil at September 30, 2022. Additionally, the Company recorded impairment of its indefinite lived brand intangible assets acquired through the Gage Acquisition of $19,200, reducing the carrying value of the brand intangibles to $57,985 at September 30, 2022.
The impairment recorded during the nine months ended September 30, 2021 related to the write-off of intellectual property at the Company’s Arise business.
Impairment of goodwill
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Impairment of goodwill | $178,314 | $5,007 |
| $ change | $173,307 | |
| % change | 3461% |
During the nine months ended September 30, 2022, as it was determined that it was more likely than not that the Michigan reporting unit's fair value was less than its carrying value, a one-step goodwill quantitative impairment test was performed. As a result of the quantitative impairment test, the Company recorded impairment of goodwill of $178,314 at its Michigan reporting unit, reducing the carrying value of the goodwill acquired through the Gage Acquisition and Pinnacle Acquisition to $nil.
The impairment recorded for the nine months ended September 30, 2021 related to the Company’s Florida reporting unit as the Company determined that the estimated cash flows of its Arise business did not support the carrying value of the intangible assets and goodwill. As a result, the company recorded impairment to reduce the balance of goodwill at its Florida reporting unit to $nil.
Revaluation of contingent consideration
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Revaluation of contingent consideration | $189 | $2,652 |
| $ change | $(2,463) | |
| % change | -93% |
The decrease in the revaluation of contingent consideration for the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021 was a result of a reduction in the liability as compared to September 30, 2021 due to payments for the earnout of State Flower of $7,040 made subsequent to September 30, 2021, reducing the amount outstanding. This decrease was partially offset by the accretion of the contingent consideration payable for KCR, which is recorded at the present value of future payments upon initial recognition.
Gain on fair value of warrants and purchase option derivative asset
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Gain on fair value of warrants and purchase option derivative asset | $(58,555) | $(43,715) |
| $ change | $(14,840) | |
| % change | 34% |
The warrant liability was remeasured to fair value at September 30, 2022 using the Black Scholes model. The Company recognized a gain during the nine months ended September 30, 2022 as a result of the reduction of the Company's share price from December 31, 2021 as compared to September 30, 2022, as well as from warrants exercised during the nine months ended September 30, 2022. The combined impact resulted in a gain on fair value of warrants of $59,373.
For the nine months ended September 30, 2022, the purchase option derivative asset related to the option to purchase an additional 6.25% of ownership of the Company's New Jersey partnership, were remeasured using the Monte Carlo simulation model and resulted in a loss of $818.
During the nine months ended September 30, 2021, the Company recognized a gain on fair value of warrants of $43,715 as a result of the decrease in the Company's share price from December 31, 2020 to September 30, 2021 as well as warrants exercised during the nine months ended September 30, 2021.
Finance and other expenses
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Finance and other expenses | $30,227 | $22,281 |
| $ change | $7,946 | |
| % change | 36% |
34
The increase in finance and other expenses for the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021 was primarily due to interest expense recognized on the loans acquired as part of the Gage Acquisition.
Transaction and restructuring costs
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Transaction and restructuring costs | $2,601 | $1,466 |
| $ change | $1,135 | |
| % change | 77% |
The increase in transaction and restructuring costs for the nine months ended September 30, 2022 was primarily due to personnel related reorganization and severance costs in Canada. The transaction and restructuring costs for the three months ended September 30, 2021 included legal costs related to the acquisitions of KCR, HMS, and Gage.
Unrealized and realized foreign exchange loss
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Unrealized and realized foreign exchange loss | $636 | $4,582 |
| $ change | $(3,946) | |
| % change | -86% |
The decrease in unrealized foreign exchange loss for the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021 was a result of the remeasurement of USD denominated liabilities recorded in C$ functional currency at the Company’s Canadian operations.
Unrealized and realized gain on investments
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Unrealized and realized loss (gain) on investments | $3 | $(6,192) |
| $ change | $6,195 | |
| % change | -100% |
The loss on investment during the nine months ended September 30, 2022 was related to the revaluation of the investments acquired through the Gage Acquisition. The gain on investment during the nine months ended September 30, 2021 related to the acquisition of the remaining 90% investment in Guadco LLC and KCR Holdings LLC.
Provision for income taxes
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Provision for income taxes | $(25,602) | $21,372 |
| $ change | $(46,974) | |
| % change | -220% |
The decrease in provision for income taxes for the nine months ended September 30, 2022 as compared to the nine months ended September 30, 2021 was primarily driven by the decrease in pre-tax book income as a result of the impairment of intangible assets and goodwill recorded by the Company during the period.
Liquidity and Capital Resources
| September 30, 2022 $$ | December 31, 2021 | |
|---|---|---|
| Cash and cash equivalents | 34,288 | 79,642 |
| Current assets | 113,397 | 143,221 |
| Non-current assets | 612,091 | 438,713 |
| Current liabilities | 172,342 | 61,044 |
| Non-current liabilities | 274,324 | 291,936 |
| Working capital | (58,945) | 82,177 |
| Total shareholders' equity | 278,822 | 228,954 |
The calculation of working capital provides additional information and is not defined under GAAP. The Company defines working capital as current assets less current liabilities. This measure should not be considered in isolation or as a substitute for any standardized measure under GAAP.
Sources of liquidity
Since its inception, the Company's primary sources of capital have been through the issuance of equity securities or debt facilities, and the Company has received aggregate net proceeds from such transactions totaling $564,896 as of September 30, 2022.
The Company expects to fund any additional future requirements through the following sources of capital:
- Cash from ongoing operations.
- Market offerings.
- Debt - the Company may seek to obtain additional debt from additional creditors.
- Sale leaseback - the Company may seek to sell and lease back its capital properties.
- Exercise of options and warrants - the Company would receive funds from exercise of options and warrants from the holders of such securities in the event they are exercised.
Capital requirements
As of September 30, 2022, there were no material changes in the Company's short-term and long-term cash requirements from those disclosed in the "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in the Company's 2021 10-K, except as those described below:
The Company has $284,231 in principal amounts of loans payable at September 30, 2022. Of this amount, $78,847 are due within the next twelve months.
At September 30, 2022, the Company had cash and cash equivalents of $34,288. As reflected in the unaudited condensed consolidated financial statements, the Company has incurred net losses for the three and nine months ended September 30, 2022 of $310,985 and $312,829, respectively, which primarily related to impairment of goodwill and intangible assets in its Michigan business (refer to Note 7), and the Company had negative cash flow from operating activities for the nine months ended September 30, 2022 of $33,431. Subsequent to the quarter end, the Company entered into a senior secured term loan in an aggregate amount of $45,478 (refer to Note 22 for further details about the loan). The Company has $55,000 of debt that becomes due on November 30, 2022 that the Company plans to refinance (refer to Note 8 for more information about the senior secured term loan that becomes due on November 30, 2022).
While the Company's cash flow and net losses for the nine months ended September 30, 2022 are indicators that raise substantial doubt about whether the Company will be able to support its operations and meet its obligations in the near term, the Company believes this concern is mitigated by steps to improve its operations and cash position, including (i) identifying access to future capital, (ii) continued sales growth from the Company's consolidated operations, and (iii) various actions that were implemented during the three months ended September 30, 2022 leading to general and administrative expense reductions. If the Company is unable to refinance its debt obligations that become due November 30, 2022 and the efforts outlined above are ineffective, there could be a material adverse effect on the results of the Company's operations and financial condition.
The Company has entered into leases for certain premises and offices for which it owes monthly lease payments. The Company has $5,809 in lease obligations due in the next twelve months. Additionally, the Company makes monthly payments on financing obligations on five properties of owned real estate. The Company has $1,887 in financing obligations due in the next twelve months.
Through the pending acquisition of AMMD, the Company has capital commitments of $10,000 to purchase all the outstanding equity, in addition to acquiring the real estate for $1,700. In addition, the Company's undiscounted contingent consideration payable is $10,734 at September 30, 2022. The contingent consideration payable relates to the Company's business acquisitions of The Apothecarium, State Flower, and KCR. Contingent consideration is based upon the potential earnout of the underlying business unit and is measured at fair value using a projection model for the business and the formulaic structure for determining the consideration under the agreement. The contingent consideration is revalued at the end of each reporting period.
The Company does not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company's results of operations or financial condition, including, and without limitation, such consideration as liquidity and capital resources.
The Company’s objective with respect to its capital management is to ensure it has sufficient cash resources to maintain its ongoing operations and finance its research and development activities, corporate and administration expenses, working capital and overall capital expenditures. Since inception, the Company has primarily financed its liquidity needs through the issuance of shares and utilization of borrowings.
Debt facilities
Canopy Growth- Canada Inc loan
On November 11, 2022, TerrAscend Canada Inc. and Canopy USA III Limited Partnership ("Canopy USA III LP"), a successor to Canopy Growth Corporation, entered into an agreement for the period commencing August 31, 2022 to (and including) November 30, 2022, subject to certain conditions, whereby Canopy USA III LP agreed to a waiver of TerrAscend Canada Inc.’s obligation to maintain the minimum current assets as set forth in the loan financing agreement with Canopy USA LLL LP (see Note 8 of the unaudited condensed consolidated financial statements referencing "Canopy Growth Canada Inc. loan").
Ilera term loan
On April 28, 2022, the Ilera term loan (refer to Note 8 of the unaudited condensed consolidated financial statements) was amended to provide WDB Holding PA, a subsidiary of the Company, with greater flexibility by resetting the minimum consolidated interest coverage ratio levels that must be satisfied at the end of each measurement period and extending the date in which WDB Holding PA is required to deliver its budget for the fiscal year ending 2021. In addition, the no-call period was extended from 18 months to 30 months, subject to a premium payment. This modification was not considered extinguishments of debt under ASC 470, Debt.
On November 11, 2022, WDB Holding PA, the Company, TerrAscend USA Inc. and the subsidiary guarantors party to the PA Credit Agreement and the PA Agent (on behalf of the required lenders) entered into an amendment to the PA Credit Agreement, pursuant to which the PA Agent and the required lenders agreed that WDB Holding PA’s obligation to maintain the consolidated interest coverage ratio as set forth in the PA Credit Agreement for the period ended September 30, 2022, shall not apply, subject to certain conditions, including (but not limited to) an obligation to enter into a subsequent amendment agreement on or before December 15, 2022, documenting certain enhancements and amendments to the PA Credit Agreement to be agreed. In addition, WDB Holding PA offered a prepayment of $5,000 pro rata to all lenders holding outstanding loans thereunder at a price equal to 103.22% of the principal amount prepaid, plus accrued and unpaid interest.
Cash Flows
Cash flows used in operating activities
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Net cash used in operating activities | $(33,431) | $(28,012) |
The increase in cash used in operating activities for the nine months ended September 30, 2022 is primarily due to an increase in loss from operations, excluding non-cash impairment losses on intangible assets and goodwill, of $32,088 from a profit of $23,148 in the prior year period, as well as changes in working capital items of $6,616.
Cash flows used in investing activities
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Net cash used in investing activities | $(12,582) | $(95,495) |
37
The net cash used in investing activities for the nine months ended September 30, 2022 primarily relates to investments in property and equipment of $24,678, primarily related to the buildout of a cultivation site in Maryland, continuing renovations at the Company's Pennsylvania cultivation site, as well as the continued buildout of the Company's Lodi alternative treatment center in New Jersey. Additionally, the Company had investments in intangible assets of $1,330, primarily related to adult use licenses in New Jersey. The cash used in investing activities is offset by cash inflows of $16,227 related to the cash acquired through the Gage Acquisition, offset by net cash paid for consideration for the Pinnacle Acquisition.
Net cash used in investing activities for the nine months ended September 30, 2021 primarily relates to cash consideration paid for the acquisition of KCR and HMS totaling $42,736. During the nine months ended September 30, 2021, the Company made payments of $25,000 related to the purchase of the additional 12.5% of the issued and outstanding equity of TerrAscend NJ from BWH NJ, LLC and Blue Marble Ventures, LLC. Additionally, the Company had investments in property and equipment of $26,706 primarily related to the buildout of the New Jersey operations and expansions in Pennsylvania cultivation and $1,739 related to deposits paid for expansion of the cultivation premises in Pennsylvania.
Cash flows from financing activities
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Net cash provided by financing activities | $5,537 | $167,935 |
During the nine months ended September 30, 2022, 7,989,436 Common Share warrants were exercised for total proceeds of $23,797 and 238,065 stock options were exercised for total gross proceeds of $361. The cash provided by financing activities was offset by payments of contingent consideration related to the acquisition of State Flower of $6,630, loan principal payments of $6,088, loan amendment fees paid on the modification of the Ilera term loan and the Gage senior secured term loan of $2,309, tax distributions paid on behalf of the partners of the New Jersey operations of $1,436, and distributions to non-controlling interests of $1,237.
Net cash provided by financing activities for the nine months ended September 30, 2021, was primarily a result of the private placement on January 28, 2021, in which the Company issued 18,115,656 Common Shares at a price of $9.64 (C$12.35) per Common Share for total proceeds of $173,477, net of share issuance costs of $1,643. Additionally, during the nine months ended September 30, 2021, 2,590,178 Common Share warrants were exercised for total proceeds of $6,777 and 829,675 stock options were exercised at $0.67-$6.93 (C$0.85-$8.82) per unit for total gross proceeds of $3,677. In addition, 1,968 Preferred Share warrants were exercised at $3,000 per unit for total gross proceeds of $3,588. The cash provided by financing activities was offset by payments of contingent consideration related to the acquisition of Ilera of $18,274.
Reconciliation of Non-GAAP Measures
In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company's ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates (i) Adjusted gross profit as gross profit adjusted for certain material non-cash items and (ii) Adjusted EBITDA as EBITDA adjusted for certain material non-cash items and certain other adjustments, which management believes are not reflective of the ongoing operations and performance. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.
The Company believes Adjusted EBITDA is a useful performance measure to assess the performance of the Company as it provides more meaningful ongoing operating results by excluding the effects of expenses that are not reflective of the Company's underlying business performance and other one-time non-recurring expenses. The table below reconciles net loss to EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2022 and 2021.
| Notes | For the Three Months Ended September 30, 2022 | September 30, 2021 | For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|---|---|---|
| Net income (loss) | $(310,985) | $55,835 | $(312,829) | $12,062 | |
| Add (deduct) the impact of: | |||||
| Provision for income taxes | (34,033) | 4,999 | (25,602) | 21,372 | |
| Finance expenses | 10,092 | 6,351 | 26,217 | 18,134 | |
| Amortization and depreciation | 7,110 | 4,200 | 19,241 | 11,250 | |
| EBITDA | (a) | (327,816) | 71,385 | (292,973) | 62,818 |
| Add (deduct) the impact of: | |||||
| Relief of fair value upon acquisition | (b) | 415 | 1,163 | 2,770 | 1,730 |
| Non-cash write downs of inventory | (c) | 6,037 | — | 11,931 | 449 |
| Vape recall | (d) | — | — | 2,965 | — |
| Share-based compensation | (e) | 2,705 | 5,178 | 10,524 | 13,393 |
| Impairment of goodwill and intangible assets | (f) | 331,242 | — | 331,242 | 8,640 |
| (Gain) loss on disposal of fixed assets | (g) | (81) | 220 | 848 | 256 |
| Revaluation of contingent consideration | (h) | 36 | (338) | 189 | 2,652 |
| Restructuring costs and executive severance | (i) | 1,443 | 450 | 1,443 | 917 |
| Legal settlements | (j) | 1,170 | — | 1,170 | 2,121 |
| Other one-time items | (k) | 1,311 | 1,365 | 4,209 | 2,487 |
| Gain on fair value of warrants and purchase option derivative asset | (l) | (5,497) | (69,016) | (58,555) | (43,715) |
| Indemnification asset release | (m) | — | 95 | 3,973 | 3,891 |
| Unrealized and realized (gain) loss on investments | (n) | (231) | — | 3 | (6,192) |
| Unrealized and realized foreign exchange loss (gain) | (o) | 586 | (1,256) | 636 | 4,582 |
| Adjusted EBITDA | $11,320 | $9,246 | $20,375 | $54,029 |
The Company calculates adjusted gross profit to adjust gross profit for the one-time relief of fair value upon acquisition, non-cash write downs of inventory, vape recall and accelerated depreciation as the Company does not believe that these impacts are reflective of ongoing operations. The table below reconciles gross profit to adjusted gross profit for the three and nine months ended September 30, 2022 and 2021.
| Notes | For the Three Months Ended September 30, 2022 | September 30, 2021 | For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|---|---|---|
| Gross profit | $24,363 | $21,497 | $62,496 | $91,274 | |
| Add (deduct) the impact of: | |||||
| Relief of fair value upon acquisition | (b) | 415 | 1,163 | 2,770 | 1,730 |
| Non-cash write downs of inventory | (c) | 6,037 | — | 11,931 | 449 |
| Vape recall | (d) | — | — | 2,965 | — |
| Facility transition costs | (p) | 107 | — | 107 | — |
| Accelerated depreciation | (q) | — | — | 238 | — |
| Adjusted gross profit | $30,922 | $22,660 | $80,507 | $93,453 |
(a) EBITDA is a non-GAAP measure and is calculated as earnings before interest, tax, depreciation and amortization.
(b) In connection with the Company's acquisitions, inventory was acquired at fair value, which included a markup or markdown for profit. Recording inventory at fair value in purchase accounting has the effect of increasing or decreasing inventory and thereby increasing or decreasing cost of sales as compared to the amounts the Company would have recognized if the inventory was sold through at cost. The write-up or down of acquired inventory represents the incremental cost of sales that were recorded during purchase accounting.
(c) Represents inventory write downs outside of the normal course of operations. These inventory write-downs were related to inventory that was deemed unsaleable in its business in Canada, as well as the write down of aged inventory to lower of cost or market which was related to the Company's operational reconfiguration of its cultivation facility in Pennsylvania.
(d) On February 4, 2022, more than 500 vape products were recalled by the Pennsylvania's Department of Health, including several of the Company's SKUs. As a result of the recall the Company recorded sales returns of $nil and $1,040 and write-downs of inventory of $nil and $1,925 for the three and nine months ended September 30, 2022, respectively.
(e) Represents non-cash share-based compensation expense.
(f) Represents impairment charges taken on the Company's intangible assets and goodwill.
(g) Represents (gain) loss taken on write-down of property and equipment.
(h) Represents the revaluation of the Company’s contingent consideration liabilities.
(i) Represents costs associated with executive severance and restructuring of business units.
(j) Represents one-time legal settlement charges.
(k) Includes one-time fees incurred in connection with the Company’s acquisitions, such as expenses related to professional fees, consulting, legal and accounting, that would otherwise not have been incurred. In addition, includes one-time charges for Sarbanes Oxley Act of 2022 implementation, as well as work completed in preparation of becoming a US filer. These fees are not indicative of the Company’s ongoing costs.
(l) Represents the gain on fair value of warrants, including effects of the foreign exchange of the US denominated preferred share warrants, as well as the revaluation of the fair value of the purchase option derivative asset.
(m) Represents the reduction to the indemnification asset related to the Apothecarium tax audit settlement and statute expirations for tax years ended September 30, 2014 and September 30, 2015.
(n) Represents unrealized and realized (gain) loss on fair value changes on strategic investments.
(o) Represents the remeasurement of USD denominated cash and other assets recorded in C$ functional currency.
(p) Represents facility transfer costs taken in Maryland due to the move of the cultivation facility from Frederick to Hagerstown.
(q) Represents accelerated depreciation taken in Maryland due to the move of the cultivation facility from Frederick and Hagerstown.
The decrease in Adjusted EBITDA and adjusted gross profit for the three and nine months ended September 30, 2022 compared to the three and nine months ended September 30, 2021 was primarily due to lower volume and resulting gross margin compression mainly related to challenging market dynamics in Pennsylvania.
Recent Accounting Pronouncements
Information regarding the Company's adoption of new accounting and reporting standards is discussed in Note 2 to the accompanying unaudited condensed consolidated financial statements in this Quarterly Report on Form 10-Q.
Descriptions of the recently issued and adopted accounting principles are included in Item 1. "Financial Statements" in Note 1, Summary of Significant Accounting Policies, to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
Critical Accounting Estimates
The condensed consolidated financial statements have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements require us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. The Company bases its estimates on historical experience and assumptions on an ongoing basis. Actual results may differ from these estimates. To the extent that there are material differences between these estimates and actual results, the Company's future financial statements will be affected.
There have been no significant changes to the critical accounting estimates from the information provided in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operation," included in the 2021 Form 10-K.
Emerging Growth Company Status
The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, the condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
The Company will remain an emerging growth company until the earlier to occur of: (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of its initial public offering, (b) in which we have total annual gross revenue of $1.235 billion or more, or (c) in which the Company is deemed to be a large accelerated filer, which means the market value of our Common Stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th; and (ii) the date on which the Company has issued more than $1.0 billion in non-convertible debt during the prior three-year period.
Market risk
As filed, 190 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes in the Company's primary risk exposures or management of market risks for the quarter ended September 30, 2022 from those disclosed in its 2021 Form 10-K.
Controls and procedures
As filed, 2,063 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
The Company's management, with the participation of its Principal Executive officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the Principal Executive Officer and Chief Financial Officer concluded that, as of September 30, 2022 the Company's disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Risk factors
As filed, 432 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Investing in the Company's Common Stock involves a high degree of risk. For a detailed discussion of the risks that affect the Company's business, please refer to the section titled “Risk Factors” in the 2021 Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 17, 2022 and as amended. There have been no material changes to the Company's risk factors as previously disclosed in the 2021 Form 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $67.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $181.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-07-01 to 2022-09-30 | $42.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2022-01-01 to 2022-09-30 | $119.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-07-01 to 2022-09-30 | $24.4m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-01-01 to 2022-09-30 | $62.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $29.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $85.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$339.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$363.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-07-01 to 2022-09-30 | −$34.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | −$25.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$313.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$316.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | −$1.23 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$1.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$1.23 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$1.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 254,355,792,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 239,567,866,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | −$33.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $24.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-09-30 | $34.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $113.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $725.5m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $172.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $446.7m | us-gaap:Liabilities |
| Long-term debt | At period end2022-09-30 | $284.2m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-09-30 | $278.8m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0000950170-22-024976. Last ingested by Listed: Nov 5, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.